QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.021840v1 70/1/206    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Related articles in MolPharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, M. Articles by Miller, L. J. Search for Related Content PubMed PubMed Citation Articles by Dong, M. Articles by Miller, L. J.

Possible Endogenous Agonist Mechanism for the Activation of Secretin Family G Protein-Coupled Receptors

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Scottsdale, Arizona

The class B family of G protein-coupled receptors contains several potentially important drug targets, yet our understanding of the molecular basis of ligand binding and receptor activation remains incomplete. Although a key role is recognized for the cysteine-rich, disulfide-bonded amino-terminal domain of these receptors, detailed insights into ligand docking and resultant conformational changes are not clear. We postulate that binding natural ligands to this domain results in a conformational change that exposes an endogenous ligand which interacts with the body of the receptor to activate it. In this work, we examined whether a synthetic peptide corresponding to a candidate region between the first and third conserved cysteines could act as an agonist. Indeed, this peptide was a weakly potent but fully efficacious agonist, stimulating a concentration-dependent cAMP response in secretin receptor-bearing cells. This effect was maintained as the peptide length was reduced from 30 to 5, and ultimately, three residues focused on the conserved residue Asp⁴⁹. The agonist potency was enhanced by cyclization through a diaminopropionic acid linker and by amino-terminal fatty acid acylation. Both ends of the cyclic peptide were shown to interact with the top of transmembrane segment 6 of the receptor, using probes with a photolabile benzoyl-phenylalanine on each end. Analogous observations were also made for two other members of this family, the vasoactive intestinal polypeptide type 1 and calcitonin receptors. These data may provide a unique molecular mechanism and novel leads for the development of small-molecule agonists acting at potential drug targets within this physiologically important receptor family.

Address correspondence to: Dr. Laurence J. Miller, Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, AZ 85259. E-mail: miller{at}mayo.edu

Related articles in MolPharm:

Class B GPCRs: A Hidden Agonist Within?

Martin Beinborn
MolPharm 2006 70: 1-4. [Abstract] [Full Text]  

This article has been cited by other articles:

				T. J. Gardella Mimetic Ligands for the PTHR1: Approaches, Developments, and Considerations IBMS BoneKEy, February 1, 2009; 6(2): 71 - 85. [Abstract] [Full Text] [PDF]

				M. Dong, P. C.-H. Lam, D. I. Pinon, P. M. Sexton, R. Abagyan, and L. J. Miller Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding Mol. Pharmacol., August 1, 2008; 74(2): 413 - 422. [Abstract] [Full Text] [PDF]

				M. Dong, F. Gao, D. I. Pinon, and L. J. Miller Insights into the Structural Basis of Endogenous Agonist Activation of Family B G Protein-Coupled Receptors Mol. Endocrinol., June 1, 2008; 22(6): 1489 - 1499. [Abstract] [Full Text] [PDF]

				S. Runge, H. Thogersen, K. Madsen, J. Lau, and R. Rudolph Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain J. Biol. Chem., April 25, 2008; 283(17): 11340 - 11347. [Abstract] [Full Text] [PDF]

				K. G. Harikumar, P. C.-H. Lam, M. Dong, P. M. Sexton, R. Abagyan, and L. J. Miller Fluorescence Resonance Energy Transfer Analysis of Secretin Docking to Its Receptor: MAPPING DISTANCES BETWEEN RESIDUES DISTRIBUTED THROUGHOUT THE LIGAND PHARMACOPHORE AND DISTINCT RECEPTOR RESIDUES J. Biol. Chem., November 9, 2007; 282(45): 32834 - 32843. [Abstract] [Full Text] [PDF]

				C. S. Lisenbee, K. G. Harikumar, and L. J. Miller Mapping the Architecture of Secretin Receptors with Intramolecular Fluorescence Resonance Energy Transfer Using Acousto-Optic Tunable Filter-Based Spectral Imaging Mol. Endocrinol., August 1, 2007; 21(8): 1997 - 2008. [Abstract] [Full Text] [PDF]

				M. Dong, P. C.-H. Lam, F. Gao, K. Hosohata, D. I. Pinon, P. M. Sexton, R. Abagyan, and L. J. Miller Molecular Approximations between Residues 21 and 23 of Secretin and Its Receptor: Development of a Model for Peptide Docking with the Amino Terminus of the Secretin Receptor Mol. Pharmacol., August 1, 2007; 72(2): 280 - 290. [Abstract] [Full Text] [PDF]

				M. Beinborn Class B GPCRs: A Hidden Agonist Within? Mol. Pharmacol., July 1, 2006; 70(1): 1 - 4. [Abstract] [Full Text] [PDF]